By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Where the characters work through the week's evidence.

How the tracks work together: The Root Room shows you how to stay in the room and have a hard health conversation without it turning into a fight. Plain Talk shows you how to work through the facts together, once the other person is open to looking. The Informed is the full evidence underneath, for when you want to check every detail yourself. Want to practice the moves yourself? Stay in the Room and Don't Rage Quit, two short training games built on the same technique, are free to play at openlabelmedia.com/games.

“Everyone keeps telling me clinical trials are a last resort,” the woman says. “That I'd be a guinea pig.”

Her husband, arms crossed in the second chair. “Because that's what they are. I've read about this. These programs are for people who've got nothing left to try. She's not signing up to be somebody's experiment.”

Nani doesn't argue. She's grateful, not for the first time, for the afternoon she spent playing Stay in the Room on her own break. It didn't teach her facts about trials. It taught her how to stay in a room with someone who has already decided to leave it.

She turns her chair to face him instead of the screen. “Can I ask what you're picturing, when you think about a clinical trial?”

He doesn't answer right away. “I don't know. A waiting list, fine print. Somebody deciding whether she's worth the risk.”

“That's a real fear, and I'm not going to talk you out of it in the next five minutes.” Nani leans back instead of leaning in.

“Here's what I can tell you. Every medicine on the market right now, the ones she's already taking, exists because someone else's family sat in a room like this one and said yes. And it isn't the last-chance version people picture. You get more monitoring in a trial, not less, extra screening, extra visits, somebody watching closer than a regular appointment ever would.”

“One more thing, and I'd rather you hear it from me than find out later. We don't run every study here. If nothing at this site fits her, that's not the end of it, it just means the right one might be somewhere else. That's worth knowing before you decide there's nothing to look for.”

He uncrosses his arms. Doesn't say yes. Doesn't leave either. “Okay,” he says finally. “Show me what you'd actually be showing her.”

Nani opens her laptop. “Let's go look.” She pulls up ClinicalTrials.gov. “Free, public, the government's own list of nearly every study running.” She types the diagnosis, sets the location, filters for who's recruiting. A handful of studies appear.

“This one's recruiting people right where she is in her illness journey. Nearest site's a state away, that's real, and it's a problem we can plan around. But look at what just happened. Nobody ran out of options. You found one nobody showed you.”

The husband looks at the screen, then at his wife. “Send me the listing.”

The line to keep: “A trial isn't the last door. It's a door most people were never shown, and sometimes somebody has to stop arguing at it long enough to actually knock.”

Nani doesn't say any of this to the couple. She writes it in her notes instead, the line she writes more often than she'd like: another family who almost didn't look, and wouldn't have if nobody in the room had known how to ask. Most people who could use a trial never find one, not because none exists, but because too few people know to look before it feels like the last option. When a study can't find enough patients in time, it runs longer than it should, or it closes before it finishes, and the treatment behind it never reaches anyone at all.

“The fix for that isn't a better pitch,” she tells her supervisor at the end of the shift. “It's more people just knowing to ask, before they're sitting in a room like that one.”

Next issue: Wednesday, we hand you the exact search Nani just ran, step by step, so you can do it yourself before your next appointment.

Every study that struggles to enroll runs longer than it needs to, or closes before it finishes, and the medicine behind it never reaches the people waiting on it. The fix isn't a sharper pitch inside the exam room, it's more people knowing to ask before they're sitting in one.

Forward this to someone, not because they need a trial today, but so they know how to ask before it feels like the last option. This week's Plain Talk covers the same ground in plain language. Subscribe to get it in your inbox at RootToRx.com.

This week's Plain Talk covers the same topic in plain language. Subscribe to get it in your inbox at RootToRx.com.

Want the full science? This issue's The Informed covers the regulatory gray zone peptides like BPC-157 sit in right now. Read it this week after Opting In: Opt-in Instructions

[1] ClinicalTrials.gov Modernization, National Library of Medicine (nlm.nih.gov/news/Modernized_ClinicalTrials.html), effective June 25, 2024.

[2] Williams RJ, Tse T, DiPiazza K, Zarin DA. "Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination." PLoS One. 2015;10(5):e0127242. Insufficient accrual was the leading cause of termination among trials not stopped for data/safety reasons (57%).

Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | TikTok: tiktok.com/@root.to.rx | YouTube: youtube.com/@roottorx | Threads: threads.com/@roottorx | Subscribe: RootToRx.com

For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States